Skip to search formSkip to main contentSkip to account menu

P-glycoprotein Inhibitor HM30181AK

Known as: HM30181AK, Pgp Inhibitor HM30181AK, HM30181A 
An inhibitor of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter P-glycoprotein (P-gp), with adjuvant activity. Upon oral… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
KX-ORAX-001: An open label, randomized, multicenter, phase III registrational study to determine the safety, tolerability, and tumor response of oraxol (HM30181A + oral paclitaxel) and its…
TPS1116 Background: Paclitaxel is used in multiple cancer types including the treatment of breast cancer after failure of… 
2018
2018
A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies.
2526Background: Oraxol is an oral formulation of paclitaxel (PTX) co-administered with the potent, selective, poorly absorbed, P… 
2018
2018
Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients.
2015
2015
Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer.
BACKGROUND Oraxol consists of paclitaxel and HM30181A, a P-glycoprotein inhibitor, to increase the oral bioavailability of… 
2014
2014
A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer
Purpose The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, and recommended… 
2008
2008
Oral paclitaxel chemotherapy for brain tumors: ideal combination treatment of paclitaxel and P-glycoprotein inhibitor.
Oral chemotherapy has many advantages over parenteral chemotherapeutics administration. To use the advantages of the oral… 
2008
2008
Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors.
P-glycoprotein (P-gp), a factor responsible for the multidrug resistance of tumors, is specifically expressed in brain… 
2008
2008
Effectively targeting BRAF in melanoma: a formidable challenge
Since the finding of activating mutation of BRAF in cutaneous melanoma we have learned to appreciate the remarkable diversity of… 
2007
2007
Characterization of Human Liver Cytochrome P-450 Enzymes Involved in the O-demethylation of a New P-glycoprotein Inhibitor HM-30181
HM-30181, 4-oxo-4H-chromene-2-carboxylic acid [2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2H… 
2006
2006
Simultaneous determination of paclitaxel and a new P-glycoprotein inhibitor HM-30181 in rat plasma by liquid chromatography with tandem mass spectrometry.
An LC-MS/MS method for the simultaneous determination of a new P-glycoprotein inhibitor 4-oxo-4H-chromene-2-carboxylic acid [2-(2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)